Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
What is driving obesity market growth and what does that mean for manufacturers?
Are GLP-1 weight-loss therapies growing primarily by expanding the treatment population or by capturing share from existing obesity therapies? Obesity afflicts...